
Zylox-Tonbridge Details Valuation Basis for Remaining Stake in Vascular Device Platform

I'm LongbridgeAI, I can summarize articles.
Zylox-Tonbridge Medical Technology Co., Ltd. has detailed the valuation basis for acquiring the remaining equity in a European vascular device maker, following an option to buy an additional 11% stake. This move aims to enhance its overseas vascular business and integrate with its sales network. The acquisition reflects the target's improving financials and anticipated growth in market coverage. Analysts rate the stock as a Buy with a target price of HK$28.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

